New vaccine for Zika that is both effective and safe
Penn researchers have developed a first-of-its-kind vaccine to fight the Zika virus that demonstrates both safety and effectiveness. Participants in a clinical trial who received three doses of the GLS-5700 vaccine developed Zika-specific antibodies with minimal negative effects. These results open the door to future clinical trials and possible government approval for the vaccine. The study, which was published earlier this month in the New England Journal of Medicine, was a joint project of the Perelman School of Medicine, the Wistar Institute, Inovio Pharmaceuticals and GeneOne Life Science, Inc.
Temperatures could accelerate the success of a Zika vaccine
As warmer temperatures herald annoying mosquitoes, the researchers are feverishly working on several promising vaccines against zika, a virus known to infect humans through the bite of this insect. The speed and debilitating effects of last year's zika outbreak in the Western Hemisphere generated a race to develop a vaccine. Just over a year after this pandemic was declared a global health emergency, a group of volunteers are undergoing preliminary testing.